News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
223,942 Results
Type
Article (4999)
Company Profile (17)
Press Release (218926)
Section
Business (82198)
Career Advice (461)
Deals (15041)
Drug Delivery (8)
Drug Development (19062)
Employer Resources (30)
FDA (3675)
Job Trends (3900)
News (120100)
Policy (7500)
Tag
2024 BioCapital Digital (2)
2024 Biotech Beach Standard (1)
2024 Pharm Country Digital (1)
2025 Lone Star Bio Digital (1)
Academia (291)
Adcomms (3)
Allergies (8)
Alliances (14758)
ALS (15)
Alzheimer's disease (238)
Antibody-drug conjugate (ADC) (8)
Approvals (3685)
Artificial intelligence (34)
Autoimmune disease (2)
Automation (2)
Bankruptcy (96)
Best Places to Work (2862)
Biosimilars (10)
Biotechnology (21)
Bladder cancer (7)
Brain cancer (7)
Breast cancer (42)
Cancer (384)
Cardiovascular disease (19)
Career advice (391)
Career pathing (2)
CAR-T (27)
Cell therapy (95)
Cervical cancer (2)
Clinical research (15931)
Collaboration (143)
Compensation (132)
Complete response letters (2)
COVID-19 (299)
CRISPR (7)
C-suite (80)
Cystic fibrosis (15)
Data (430)
Depression (5)
Diabetes (35)
Diagnostics (2028)
Digital health (3)
Diversity, equity & inclusion (12)
Drug discovery (15)
Drug pricing (6)
Drug shortages (1)
Duchenne muscular dystrophy (8)
Earnings (40420)
Editorial (1)
Employer branding (6)
Employer resources (31)
Events (37524)
Executive appointments (261)
FDA (3879)
Featured Employer (6)
Fibrodysplasia Ossificans Progressiva (1)
Frontotemporal dementia (2)
Funding (157)
Gene editing (14)
Generative AI (2)
Gene therapy (39)
GLP-1 (102)
Government (407)
Guidances (15)
Healthcare (5031)
Huntington's disease (1)
IgA nephropathy (2)
Immunology and inflammation (11)
Indications (5)
Infectious disease (313)
Inflammatory bowel disease (24)
Inflation Reduction Act (2)
Influenza (3)
Intellectual property (13)
Interviews (53)
IPO (7810)
IRA (3)
Job creations (1120)
Job search strategy (360)
Kidney cancer (6)
Labor market (4)
Layoffs (99)
Leadership (4)
Legal (2329)
Liver cancer (17)
Lung cancer (42)
Lymphoma (22)
Management (10)
Manufacturing (43)
MASH (24)
Medical device (3849)
Medtech (3850)
Mergers & acquisitions (7400)
Metabolic disorders (105)
Multiple sclerosis (5)
NASH (6)
Neurodegenerative disease (7)
Neuropsychiatric disorders (1)
Neuroscience (313)
NextGen: Class of 2025 (1673)
Non-profit (727)
Northern California (793)
Now hiring (2)
Obesity (48)
Opinion (30)
Ovarian cancer (14)
Pain (10)
Pancreatic cancer (12)
Parkinson's disease (19)
Partnered (4)
Patents (20)
Patient recruitment (23)
Peanut (4)
People (24445)
Pharmaceutical (5)
Pharmacy benefit managers (1)
Phase I (4752)
Phase II (6922)
Phase III (5504)
Pipeline (392)
Policy (4)
Postmarket research (625)
Preclinical (1848)
Press Release (66)
Prostate cancer (25)
Psychedelics (3)
Radiopharmaceuticals (105)
Rare diseases (60)
Real estate (1873)
Recruiting (8)
Regulatory (5070)
Reports (13)
Research institute (299)
Resumes & cover letters (68)
Rett syndrome (2)
Schizophrenia (17)
Series A (24)
Series B (17)
Sickle cell disease (7)
Southern California (584)
Special edition (1)
Sponsored (3)
Startups (1007)
Stomach cancer (1)
Supply chain (9)
United States (6086)
Vaccines (31)
Venture capitalists (2)
Webinars (4)
Weight loss (19)
Women's health (1)
Date
Today (26)
Last 7 days (222)
Last 30 days (921)
Last 365 days (10504)
2025 (1738)
2024 (11031)
2023 (13196)
2022 (18661)
2021 (19680)
2020 (18242)
2019 (13207)
2018 (10205)
2017 (10004)
2016 (9160)
2015 (12119)
2014 (9587)
2013 (7707)
2012 (8329)
2011 (8796)
2010 (8634)
Location
Africa (183)
Alabama (13)
Alaska (2)
Arizona (54)
Arkansas (1)
Asia (11404)
Australia (1592)
California (1641)
Canada (621)
China (53)
Colorado (70)
Connecticut (84)
Delaware (23)
Europe (24315)
Florida (219)
Georgia (28)
Idaho (23)
Illinois (104)
India (4)
Indiana (55)
Japan (58)
Kansas (24)
Kentucky (10)
Louisiana (5)
Maine (38)
Maryland (198)
Massachusetts (1346)
Michigan (81)
Minnesota (127)
Mississippi (1)
Missouri (19)
Montana (16)
Nebraska (12)
Nevada (21)
New Hampshire (15)
New Jersey (491)
New Mexico (5)
New York (415)
North Carolina (296)
North Dakota (2)
Northern California (793)
Ohio (49)
Oklahoma (4)
Oregon (3)
Pennsylvania (299)
Rhode Island (11)
South America (274)
South Carolina (3)
Southern California (584)
Tennessee (32)
Texas (193)
Utah (54)
Virginia (33)
Washington D.C. (7)
Washington State (143)
West Virginia (2)
Wisconsin (17)
223,942 Results for "yuhan corporation".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Ubix Therapeutics and Yuhan Announce Exclusive License Agreement for UBX-103, an Oral Small Molecule AR Degrader for Treatment of Metastatic Castration Resistant Prostate Cancer
Ubix Therapeutics, Inc., a biotechnology company discovering and developing innovative oncology therapeutics based on targeted protein degradation (TPD), announced today that it has entered into an exclusive license agreement with Yuhan to develop and commercialize preclinical androgen receptor (AR) degrader program, UBX-103.
July 1, 2024
·
2 min read
Yuhan Corporation and J INTS BIO inked a licensing agreement for a New Drug Candidate targeting HER2 NSCLC
Yuhan Corporation announced on the 30th of May that it has signed an in-license agreement with J INTS BIO for a Tyrosine Kinase Inhibitor targeting HER2, ‘JIN-A04'.
May 31, 2023
·
1 min read
Press Releases
Daxor Corporation CEO and President Michael Feldschuh Provides Corporate Update in Letter to Shareholders
March 4, 2025
·
13 min read
Press Releases
Orion Corporation: The Board of Directors of Orion Corporation decided on incentive programs for the company’s key persons
February 25, 2025
·
3 min read
Press Releases
Hemostemix Provides Corporate Update
February 14, 2025
·
6 min read
Press Releases
Kelyniam Corporate Update
January 21, 2025
·
2 min read
Press Releases
Mesoblast Financial Results and Corporate Update Webcast
February 26, 2025
·
2 min read
Press Releases
Daxor Corporation to Host Investor Conference Call to Discuss Fiscal Year 2024 Financial Results and Provide a Corporate Update on March 6, 2025
March 5, 2025
·
2 min read
Press Releases
Notice to the Annual General Meeting of Orion Corporation
February 25, 2025
·
20 min read
Press Releases
OS Therapies Provides Corporate Update
February 4, 2025
·
14 min read
1 of 22,395
Next
